New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016 - Wikidata - awgldk - TriplyDB

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

http://www.wikidata.org/entity/Q33814908

about

Recent Successes and Future Directions in Immunotherapy of Cutaneous Melanoma.DNA repair defects and implications for immunotherapy

P2860

Q47134263-AC097D84-7646-4F3B-9C60-E43BD2152DD6 Q57057014-9E468BAD-DF36-44F8-A9EA-8B5E9B1CE7F4

P2860

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016

http://www.wikidata.org/entity/Q33814908

description

2017 nî lūn-bûn

@nan

2017 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

name

New Cancer Immunotherapy Agent ...... Immunotherapy of Cancer, 2016

@ast

New Cancer Immunotherapy Agent ...... Immunotherapy of Cancer, 2016

@en

type

label

New Cancer Immunotherapy Agent ...... Immunotherapy of Cancer, 2016

@ast

New Cancer Immunotherapy Agent ...... Immunotherapy of Cancer, 2016

@en

prefLabel

New Cancer Immunotherapy Agent ...... Immunotherapy of Cancer, 2016

@ast

New Cancer Immunotherapy Agent ...... Immunotherapy of Cancer, 2016

@en

P1433

Q33814908-058B8335-5793-4550-8647-48A14C3639D3

P1476

Q33814908-DD33CA5D-CE27-45F6-B40F-81E55B099A91

P2093

Q33814908-348BAEE7-1EEF-4346-89A1-8606277DE87D

Q33814908-3824B8A8-2FB8-4465-9C96-E47CD698CF37

Q33814908-3FCE6DFB-03F0-4AB3-A7D4-64440D8ECE80

Q33814908-421DFF8D-F715-408F-893B-94BD82A6ECDD

Q33814908-61092FD6-D101-49DE-84C8-30F1312287A1

Q33814908-616EEB3F-E128-4FBE-8621-F1F91ADFFD0F

Q33814908-89D3C828-1E00-41D2-BBBA-FBB8C24B7029

Q33814908-9647616C-DEE2-4693-8D31-495D0994A8FA

Q33814908-A7A52003-2500-42B3-A97C-FA040511A7F4

Q33814908-B14D731E-033B-401A-AD72-AFBE2578A78B

P275

Q33814908-E12AFC34-8F5F-4594-A600-0890ABE4BEE2

P2860

Q33814908-09C94EDF-6967-4710-8E6F-9105D07D3273

Q33814908-0C443BE7-04D5-4AED-B7C8-A60DEFA11D6F

Q33814908-1294F235-733D-4D3C-9525-0288E86DF924

Q33814908-1CAD2DA1-4819-4E2B-AEA8-F1F45EC7E887

Q33814908-1CE06961-FF21-4E16-846F-662514FB3054

Q33814908-201DE715-AC09-4BDD-8FE9-3A29FF62A4F8

Q33814908-304D4A7C-5234-4FF2-8C5F-6675FD86890D

Q33814908-3D8B4CFA-11F9-4560-B8FF-26351E44CB90

Q33814908-3D9DDA2E-044D-442B-9987-84C3D883FAC4

Q33814908-4B37EFCF-E9F0-4251-AA10-3037F2847F96

P2888

Q33814908-90C562E7-E422-463A-B79A-D9ACDBCD6150

P304

Q33814908-9BCF3DB6-FA7A-4B6D-A3F5-5F9457C6C106

P31

Q33814908-A117ACD8-3236-4E87-A22E-1BDB36F6C095

P356

Q33814908-480806B3-7B4B-449E-9BC3-2DB8C234F208

P478

Q33814908-386E4ADE-00F1-46DD-8786-A4A1B0909BA4

P50

Q33814908-EA639A19-0E6A-4AC6-A85D-92C9D5FB56B9

P5008

Q33814908-16B0D3E5-FFBC-408C-8F9E-F745695FFE53

P577

Q33814908-936091B4-CB48-4159-AD9B-BB63BCC6E7D7

P6179

Q33814908-70A1BC92-3A8E-4887-9B7D-D1ABBCF15BEC

P698

Q33814908-7DF1D7D5-CD22-4E82-BD91-D85748BD4B48

P921

Q33814908-0429B3CA-8453-46AB-B330-BB44803182A4

Q33814908-2E7EF622-C0E2-44A2-BAB5-53F723063E98

P932

Q33814908-85563E2A-AF04-4E51-BA5B-96BAC4FD399B

P356

S40425-017-0253-2

P1433

Journal for Immunotherapy of Cancer

P1476

New Cancer Immunotherapy Agent ...... Immunotherapy of Cancer, 2016

@en

P2093

Adi Diab

http://www.w3.org/2001/XMLSchema#string

Adrian Bot

http://www.w3.org/2001/XMLSchema#string

Bryan A Irving

http://www.w3.org/2001/XMLSchema#string

Charles G Drake

http://www.w3.org/2001/XMLSchema#string

David Tuck

http://www.w3.org/2001/XMLSchema#string

Edward Cha

http://www.w3.org/2001/XMLSchema#string

Elizabeth Evans

http://www.w3.org/2001/XMLSchema#string

Frederic Triebel

http://www.w3.org/2001/XMLSchema#string

Gordon J Freeman

http://www.w3.org/2001/XMLSchema#string

Jane L Grogan

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution 4.0 International

P2860

First-line chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity

The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function

The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity

Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors

Nivolumab plus ipilimumab in advanced melanoma.

Myeloid-derived suppressor cells as regulators of the immune system

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions

P2888

s40425-017-0253-2

P304

50

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S40425-017-0253-2

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P50

P5008

P577

2017-06-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1086009470

http://www.w3.org/2001/XMLSchema#string

P698

28649381

http://www.w3.org/2001/XMLSchema#string

P921

P932

5477277

http://www.w3.org/2001/XMLSchema#string